The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press27110.17650/1818-8338-2016-10-3-10-14EDITORIALРЕДАКЦИОННАЯ СТАТЬЯSARCOPENIA AND OVERLAPPING SYNDROMES: THEIR VALUE IN CLINICAL PRACTICEСАРКОПЕНИЯ И ПЕРЕКРЕСТНЫЕ СИНДРОМЫ – ЗНАЧЕНИЕ В КЛИНИЧЕСКОЙ ПРАКТИКЕShostakN. A.ШостакН. А.
Russian Federation

Acad.A. I. Nesterov Department of Faculty Therapy, 

1 Ostrovityanovа St., Moscow 117997

Кафедра факультетской терапии им. акад. А.И. Нестерова,

117997 Москва, ул. Островитянова, 1

MuradyantzA. A.МурадянцА. А.
Russian Federation

Acad.A. I. Nesterov Department of Faculty Therapy, 

1 Ostrovityanovа St., Moscow 117997

Кафедра факультетской терапии им. акад. А.И. Нестерова,

117997 Москва, ул. Островитянова, 1

elitarsoft@list.ruKondrashovA. A.КондрашовА. А.
Russian Federation

Acad.A. I. Nesterov Department of Faculty Therapy, 

1 Ostrovityanovа St., Moscow 117997

Кафедра факультетской терапии им. акад. А.И. Нестерова,

117997 Москва, ул. Островитянова, 1

N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России1507201610310140101201701012017Copyright ©; 2016, Shostak N.A., Muradyantz A.A., Kondrashov A.A.Copyright ©; 2016, Шостак Н.А., Мурадянц А.А., Кондрашов А.А.2016Shostak N.A., Muradyantz A.A., Kondrashov A.A.Шостак Н.А., Мурадянц А.А., Кондрашов А.А.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/271

Sarcopenia and overlapping syndromes, such as decrepitude and cachexia, are important medical and social problems due to their high prevalence and association with unfavorable outcomes. The article describes some issues of terminology, classification and differentiation of sarcopenia, decrepitude and cachexia, main diagnostic principles as well as different sarcopenia phenotypes (like sarco-osteoporosis sarcopenic and osteosarcopenic obesity). Identification of sarcopenia secondary forms associated with low physical activity, eating disorders or chronic illnesses (including inflammatory ones) was an important achievement for better understanding of the disease. Studying of sarcopenia in people with rheumatoid arthritis is a matter of particular interest.

Саркопения и перекрестные синдромы, такие как немощность и кахексия, являются важными медико-социальными проблемами ввиду их значительной распространенности и ассоциации с неблагоприятными исходами. В статье рассмотрены вопросы терминологии, классификации и дифференциации саркопении, немощности и кахексии; представлены основные подходы к диагностике, а также различные фенотипы саркопении в виде саркоостеопороза, саркопенического и остеосаркопенического ожирения. Важным достижением в понимании саркопении явилось выделение вторичных форм, ассоциированных с низкой физической активностью, нарушением питания или хроническими заболеваниями, в том числе воспалительными. Особый интерес вызывает изучение саркопении у больных ревматоидным артритом.

sarcopeniadecrepitudecachexiaosteoporosissarco-osteoporosissarcopenic obesityosteosarcopenic obesityrheumatoid arthritisdual-energy X-ray absorptiometryappendicular lean mass indexbone mineral densitymyostatinсаркопениянемощностькахексияостеопорозсаркоостеопорозсаркопеническое ожирениеостеосаркопеническое ожирениеревматоидный артритдвухэнергетическая рентгеновская абсорбциометрияиндекс аппендикулярной тощей массыминеральная плотность костимиостатин1. Всемирный доклад о старении и здоровье. ВОЗ, 2016http://apps.who.int/iris/bitstream/10665/186463/10/9789244565049_rus. pdf. [World report on aging and health. WHO, 2016 http://apps.who.int/iris/bitstream/10665/186463/10/9789244565049_rus.pdf. (In Russ.)].Всемирный доклад о старении и здоровье. ВОЗ, 2016http://apps.who.int/iris/bitstream/10665/186463/10/9789244565049_rus. pdf. [World report on aging and health. WHO, 2016 http://apps.who.int/iris/bitstream/10665/186463/10/9789244565049_rus.pdf. (In Russ.)].2. Cruz-JentoftA. J., BaeyensJ. P., BauerJ. M. etal. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39(4):412–23.Cruz-JentoftA. J., BaeyensJ. P., BauerJ. M. etal. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39(4):412–23.3. Baumgartner R.N., Koehler K.M., Gallagher D. et al. Epidemiology of sarcopenia among theelderly in New Mexico. Am J Epidemiol 1998; 147(8):755–63.Baumgartner R.N., Koehler K.M., Gallagher D. et al. Epidemiology of sarcopenia among theelderly in New Mexico. Am J Epidemiol 1998; 147(8):755–63.4. Peterson S. J, Braunschweig C.A. Prevalence of Sarcopenia and Associated Outcomes in the Clinical Setting. Nutr Clin Pract 2016;31(1):40–8.Peterson S. J, Braunschweig C.A. Prevalence of Sarcopenia and Associated Outcomes in the Clinical Setting. Nutr Clin Pract 2016;31(1):40–8.5. Yakabe M., Ogawa S., Akishita M. Clinical Manifestations and Pathophysiology of Sarcopenia. RNA and Transcription 2015;1(2):10–7.Yakabe M., Ogawa S., Akishita M. Clinical Manifestations and Pathophysiology of Sarcopenia. RNA and Transcription 2015;1(2):10–7.6. Messina C., Monaco C.G., Ulivieri F.M. et al. Dual-energy X-ray absorptiometry body composition in patients with secondary osteoporosis. Eur J Radiol 2016;85(8):1493–8.Messina C., Monaco C.G., Ulivieri F.M. et al. Dual-energy X-ray absorptiometry body composition in patients with secondary osteoporosis. Eur J Radiol 2016;85(8):1493–8.7. Dodds R.M., Sayer A.A. Sarcopenia, frailty and mortality: the evidence is growing. Age Ageing 2016;45(5):570–1.Dodds R.M., Sayer A.A. Sarcopenia, frailty and mortality: the evidence is growing. Age Ageing 2016;45(5):570–1.8. Fried L.P., Tangen C.M., Walston J. et al. Frailty in Older Adults: Evidence for a Phenotype. J Gerontol A Biol Sci Med Sci2001;56(3):М146–56.Fried L.P., Tangen C.M., Walston J. et al. Frailty in Older Adults: Evidence for a Phenotype. J Gerontol A Biol Sci Med Sci2001;56(3):М146–56.9. Evans W.J., Morley J.E., Argilés J. et al. Cachexia: a new defenition. Clin Nutr 2008;27(6):793–9.Evans W.J., Morley J.E., Argilés J. et al. Cachexia: a new defenition. Clin Nutr 2008;27(6):793–9.10. Kizilarslanoglu M.C., Kuyumcu M.E., Yesil Y, Halil M. Sarcopenia in critically ill patients. J Anesth 2016;30(5):884–90.Kizilarslanoglu M.C., Kuyumcu M.E., Yesil Y, Halil M. Sarcopenia in critically ill patients. J Anesth 2016;30(5):884–90.11. Shachar S.S., Williams G.R., Muss H.B., Nishijima T.F. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer 2016;57:58–67.Shachar S.S., Williams G.R., Muss H.B., Nishijima T.F. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer 2016;57:58–67.12. Collamati A., Marzetti E., Calvani R. et al. Sarcopenia in heart failure: mechanisms and therapeutic strategies. J Geriatr Cardiol 2016;13(7):615–24.Collamati A., Marzetti E., Calvani R. et al. Sarcopenia in heart failure: mechanisms and therapeutic strategies. J Geriatr Cardiol 2016;13(7):615–24.13. Hirai K., Ookawara S., Morishita Y. Sarcopenia and Physical Inactivity in Patients With Chronic Kidney Disease. Nephrourol Mon 2016;26;8(3):e37443.Hirai K., Ookawara S., Morishita Y. Sarcopenia and Physical Inactivity in Patients With Chronic Kidney Disease. Nephrourol Mon 2016;26;8(3):e37443.14. Мясоедова С.Е., Рубцова О.А., Мясоедова Е.Е. Композиционный состав тела и минеральная плотность кости у женщин при ревматоидном артрите. Клиницист 2016;10(3):41–6.Мясоедова С.Е., Рубцова О.А., Мясоедова Е.Е. Композиционный состав тела и минеральная плотность кости у женщин при ревматоидном артрите. Клиницист 2016;10(3):41–6.15. Shostak N.A., Muradyants A.A., Kondrashov A.A. et al. Sarcopenia in patients with rheumatoid arthritis. J Frailty Aging 2014;3(1):61.Shostak N.A., Muradyants A.A., Kondrashov A.A. et al. Sarcopenia in patients with rheumatoid arthritis. J Frailty Aging 2014;3(1):61.16. Crepaldi G., Maggi S. Sarcopenia and osteoporosis: а hazardous duet. J Endocrinol Invest 2005;28(10 Suppl):66–8.Crepaldi G., Maggi S. Sarcopenia and osteoporosis: а hazardous duet. J Endocrinol Invest 2005;28(10 Suppl):66–8.17. Walsh M.C., Hunter G.R., Livingstone M.B. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int 2006;17(1):61–7.Walsh M.C., Hunter G.R., Livingstone M.B. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int 2006;17(1):61–7.18. Kawao N., KajiH. Interactions between muscle tissues and bone metabolism. J Cell Biochem 2015;116(5):687–95.Kawao N., KajiH. Interactions between muscle tissues and bone metabolism. J Cell Biochem 2015;116(5):687–95.19. Kaji H. Effects of myokines on bone. Bonekey Rep 2016;5:826.Kaji H. Effects of myokines on bone. Bonekey Rep 2016;5:826.20. Choi K.M. Sarcopenia and sarcopenic obesity. Korean J Intern Med 2016;31(6): 1054–60.Choi K.M. Sarcopenia and sarcopenic obesity. Korean J Intern Med 2016;31(6): 1054–60.21. Wannamethee S.G., Atkins J.L. Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc 2015; 74(4):405–12.Wannamethee S.G., Atkins J.L. Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc 2015; 74(4):405–12.22. Tian S., Xu Y. Association of sarcopenic obesity with the risk of all-cause mortality: a meta-analysis of prospective cohort studies. Geriatr Gerontol Int 2016;169(2): 155–66.Tian S., Xu Y. Association of sarcopenic obesity with the risk of all-cause mortality: a meta-analysis of prospective cohort studies. Geriatr Gerontol Int 2016;169(2): 155–66.